This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Myeloid sarcoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

extramedullary myeloid tumour (myeloid sarcoma, granulocytic sarcoma, chloroma)

Myeloid sarcoma is a tumour mass which consists of myeloid blasts and is seen at anatomical sites other than the bone marrow e.g. - most commonly in skin, lymph nodes, gastrointestinal tract, bone, soft tissue, and testis (1).

Myeloid sarcoma may arise:

  • de novo as a primary manifestation of AML in patients with no medullary evidence of leukaemia
  • simultaneously with marrow disease at presentation;
  • as an isolated focus of relapse " simultaneously with marrow disease at relapse (2)

Predisposing factors of extramedullary disease include:

  • t(8;21) translocation or inv(16)
  • high presenting white cell count
  • lack of Auer rods
  • poor nutrition (1)

Diagnosis is established through cytochemical and/or immunohistochemical analyses (1). Systemic antileukaemic chemotherapy should be given to patients who present with de novo or in relapse with extramedullary leukaemia. Surgical or radiotherapeutic approaches should be reserved for patients whose disease does not resolve with initial therapy (2).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.